Cell Therapeutics, Inc. announced preclinical data presented at the 19th annual AACR-NCI-EORTC Symposium show its bis-platinate drug candidates, CT-47613 and CT-47609, kill tumors refractory to currently marketed platinum agents carboplatin, cisplatin and oxaliplatin.
Read More...
[Source: Yahoo! News Search Results for testicular cancer]
Wednesday, October 24, 2007
First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors ... (PR Newswire via Yahoo! Finance)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment